From the Crypt: Rheumatology Dead Word Cemetery Arthritis, Rheumatic Disease and Rheumatology cover a catalogue of ageless disorders w/decades, if not centuries, of history behind them.Enjoy our blog on retired Rheum sayings, as so decreed by RheumNow. https://t.co/WyBFEVa1h5 https://t.co/eE3HQ4N5Ia

2022 New Drug Approvals Download today! https://t.co/nz91Ckw0AZ https://t.co/QieTvcqjcy

One week away! #ACR22 https://t.co/bvFCfFpQom

“I am looking forward to the ACR to hear about the ground-breaking results from basic science to the new treatments. I am delighted to be part of the RheumNow faculty covering the many topics from #ACR22. “ Follow Dr. Chan at @synovialjoints for real-time coverage of #ACR22. https://t.co/i6OZRHlBaE

New regulatory decisions about JAK inhibitors and why do women with rheumatic diseases have unfair outcomes? This and more on the latest RheumNow podcast. https://t.co/4YBqHjI3VL https://t.co/g2pE72pyEk

“At the ACR I am looking forward to meeting colleagues in person, having some great food in Philadelphia and to learning alot as a RheumNow reporter!” Dr. Janet Pope is back for #ACR22 as a RheumNow reporter, sharing real-time coverage on many topics. Follow her @Janetbirdope https://t.co/ROD7oan4KZ

SLE T2T - Lupus Low Disease Activity State Predicts Outcomes A prospective study shows that T2T with a goal of LLDAS and remission has been shown to improve mortality risk. https://t.co/WRaqjdVi9G https://t.co/3guKt0Qby9

2022 CDC Clinical Practice Guideline on Opioid Prescribing The CDC has updated its Guideline for Prescribing Opioids for Chronic Pain and includes recommendations for managing acute, subacute, and chronic pain. https://t.co/aFE4fUpIWn https://t.co/kG8QlVy2bG

Population study shows among vaccinated gout pts, COVID breakthrough infection occurred in @ 4.68/1K Pt-mos vs 3.76/1K Pt-mos in non-Gout persons. Gout w/ Covid had More Hosp (aHR=1.30) & death (aHR=1.36), moreso in Women w/ gout (aHR 1.55 & 2.46) https://t.co/ViwiPzqTbZ https://t.co/BrXd6pbgRI

Multinatinal cross-sectional survey of 2270 PsA pts shows despite comparable Dz duration, presentation, biologic use (54%), Women had worse QOL, more disability and work activity impairment (but less comorbidities) https://t.co/1KbDuxaMFf https://t.co/SsbSHQNsPV

BIOBADASER registry study of 969 axSpA pts (315 females, 654 males; 2000-2019) who initiated a TNFi shows nonresponse (BASDAI50) was more likely in women (p=0.018), older age at the start of TNFi therapy. https://t.co/Zp7PWhEMav https://t.co/1XY0dC0QCW

Single center study from UAB shows 72 gout pts treated & D/C from ED were Rx w/ steroids (64%), opioids (63%), NSAIDs (43%), colchicine (32%). But only 26/72 (36%) had subsequent outpatient clinic visit for gout. https://t.co/I8jjqIqJXd https://t.co/05YSibd6iz